v3.26.1
Balance Sheet Information (Tables)
 6 Months Ended
Jun. 30, 2026
Balance Sheet Related Disclosures [Abstract]  
Schedule of Cash and Cash Equivalents
A summary of cash and cash equivalents and restricted cash is as follows:
June 30, 2026December 31, 2025
Cash and Cash Equivalents$7,076,533 $8,696,570 
Restricted Cash, Non-current4,706 4,566 
Total Cash, Cash Equivalents and Restricted Cash$7,081,239 $8,701,136 
Schedule of Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
June 30, 2026December 31, 2025
Cash and Cash Equivalents$7,076,533 $8,696,570 
Restricted Cash, Non-current4,706 4,566 
Total Cash, Cash Equivalents and Restricted Cash$7,081,239 $8,701,136 
Schedule of Short term Investments
The following table summarizes short-term investments as of June 30, 2026 and December 31, 2025:
As of June 30, 2026
Unrealized
Amortized Cost
Gains
Losses
Estimated Fair Value
US Treasuries$109,604 $— $(1)$109,603 
Government Agency Securities6,071,500 — (6,186)6,065,314 
Corporate Debt Securities3,590,565 169 (3,657)3,587,077 
Total Short-term Investments$9,771,669 $169 $(9,844)$9,761,994 
As of December 31, 2025
Unrealized
Amortized Cost
Gains
Losses
Estimated Fair Value
Government Agency Securities$5,171,407 $4,633 $— $5,176,040 
Corporate Debt Securities3,211,460 5,013 (1)3,216,473 
Total Short-term Investments$8,382,867 $9,646 $(1)$8,392,513 
Schedule of Debt Securities, Available-for-Sale
The following table summarizes the maturities of the Company's short-term investments at June 30, 2026 and December 31, 2025:
As of June 30, 2026
Amortized CostEstimated Fair Value
Due in one year or less$9,771,669 $9,761,994 
Total Short-term Investments$9,771,669 $9,761,994 
As of December 31, 2025
Amortized CostEstimated Fair Value
Due in one year or less$8,382,867 $8,392,513 
Total Short-term Investments$8,382,867 $8,392,513 
Schedule of Available-for-Sale Investments Gross Unrealized Losses and Fair Value
The following table shows the Company's available-for-sale investments' gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at June 30, 2026 and December 31, 2025:
As of June 30, 2026
Less than 12 months
CountFair ValueUnrealized Losses
US Treasuries1 $109,603 $(1)
Government Agency Securities19 $6,065,314 $(6,186)
Corporate Debt Securities32 $2,745,505 $(3,177)
Total52 $8,920,422 $(9,364)
As of December 31, 2025
Less than 12 months
CountFair ValueUnrealized Losses
Corporate Debt Securities1 $76,056 $(1)
Total1 $76,056 $(1)
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
June 30, 2026December 31, 2025
Prepaid Research and Development$847,944 $841,723 
Prepaid General and Administrative192,872 211,501 
Prepaid Insurance86,666 88,580 
Total Prepaid Expenses and Other Current Assets$1,127,482 $1,141,804 
Schedule of Tax and Other Receivables
Tax and other receivables consist of the following:
June 30, 2026December 31, 2025
Income Tax Receivables$1,028,326 $1,028,326 
Research and Development Tax Credit Receivables
737,032 713,719 
Other Tax Receivables49,721 51,414 
Total Tax and Other Receivables$1,815,079 $1,793,459 
Schedule of Accrued Expenses
Accrued expenses consist of the following:
June 30, 2026December 31, 2025
Payroll and Benefits$771,798 $1,275,602 
Clinical Trials992,326 821,648 
Professional Fees99,451 83,278 
Income Tax65,982 142,096 
Other52,016 84,107 
Total Accrued Expenses$1,981,573 $2,406,731